FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W246691693> ?p ?o ?g. }

• W246691693 endingPage "294" @default.
• W246691693 startingPage "279" @default.
• W246691693 abstract "Human ceruloplasmin (CP) is a multifunctional copper-binding protein produced in the liver. CP oxidizes Fe(2+) to Fe(3+), decreasing the concentration of Fe(2+) available for generating harmful oxidant species. CP is also a potent inhibitor of leukocyte myeloperoxidase (MPO) (Kd=130nM), a major source of oxidants in vivo. Rheumatoid arthritis (RA) is an inflammatory autoimmune disease affecting flexible joints and characterized by activation of both inflammatory and coagulation processes. Indeed, the levels of CP, MPO, and thrombin are markedly increased in the synovial fluid of RA patients. Here we show that thrombin cleaves CP in vitro at (481)Arg-Ser(482) and (887)Lys-Val(888) bonds, generating a nicked species that retains the native-like fold and the ferroxidase activity of the intact protein, whereas the MPO inhibitory function of CP is abrogated. Analysis of the synovial fluid of 24 RA patients reveals that CP is proteolytically degraded to a variable extent, with a fragmentation pattern similar to that observed with thrombin in vitro, and that proteolysis is blocked by hirudin, a highly potent and specific thrombin inhibitor. Using independent biophysical techniques, we show that thrombin has intrinsic affinity for CP (Kd=60-270nM), independent of proteolysis, and inhibits CP ferroxidase activity (KI=220±20nM). Mapping of thrombin binding sites with specific exosite-directed ligands (i.e., hirugen, fibrinogen γ'-peptide) and thrombin analogues having the exosites variably compromised (i.e., prothrombin, prethrombin-2, βT-thrombin) reveals that the positively charged exosite-II of thrombin binds to the negatively charged upper region of CP, while the protease active site and exosite-I remain accessible. These results suggest that thrombin can exacerbate inflammation in RA by impairing the MPO inhibitory function of CP via proteolysis and by competitively inhibiting CP ferroxidase activity. Notably, local administration of hirudin, a highly potent and specifc thrombin inhibitor, reduces the concentration of active MPO in the synovial fluid of RA patients and has a beneficial effect on the clinical symptoms of the disease." @default.
• W246691693 created "2016-06-24" @default.
• W246691693 creator A5011050819 @default.
• W246691693 creator A5033952822 @default.
• W246691693 creator A5044343654 @default.
• W246691693 creator A5045131182 @default.
• W246691693 creator A5060052335 @default.
• W246691693 creator A5061755880 @default.
• W246691693 creator A5078756031 @default.
• W246691693 creator A5084663726 @default.
• W246691693 date "2015-09-01" @default.
• W246691693 modified "2023-10-17" @default.
• W246691693 title "Thrombin inhibits the anti-myeloperoxidase and ferroxidase functions of ceruloplasmin: relevance in rheumatoid arthritis" @default.
• W246691693 cites W1664764813 @default.
• W246691693 cites W1888945488 @default.
• W246691693 cites W1899503782 @default.
• W246691693 cites W1965159385 @default.
• W246691693 cites W1970638752 @default.
• W246691693 cites W1970822699 @default.
• W246691693 cites W1971776675 @default.
• W246691693 cites W1972523888 @default.
• W246691693 cites W1973480138 @default.
• W246691693 cites W1981780309 @default.
• W246691693 cites W1981975621 @default.
• W246691693 cites W1983263560 @default.
• W246691693 cites W1985013645 @default.
• W246691693 cites W1985031469 @default.
• W246691693 cites W1985776773 @default.
• W246691693 cites W1986794972 @default.
• W246691693 cites W1987550011 @default.
• W246691693 cites W1990141041 @default.
• W246691693 cites W2001052209 @default.
• W246691693 cites W2003029464 @default.
• W246691693 cites W2004422784 @default.
• W246691693 cites W2009860496 @default.
• W246691693 cites W2010020730 @default.
• W246691693 cites W2015367504 @default.
• W246691693 cites W2016982324 @default.
• W246691693 cites W2018575563 @default.
• W246691693 cites W2025209734 @default.
• W246691693 cites W2026599765 @default.
• W246691693 cites W2029677015 @default.
• W246691693 cites W2044183048 @default.
• W246691693 cites W2048680212 @default.
• W246691693 cites W2054203906 @default.
• W246691693 cites W2055430707 @default.
• W246691693 cites W2055805017 @default.
• W246691693 cites W2059149560 @default.
• W246691693 cites W2060510783 @default.
• W246691693 cites W2066230257 @default.
• W246691693 cites W2067354761 @default.
• W246691693 cites W2067606305 @default.
• W246691693 cites W2071965156 @default.
• W246691693 cites W2072730036 @default.
• W246691693 cites W2078745658 @default.
• W246691693 cites W2085505664 @default.
• W246691693 cites W2087571436 @default.
• W246691693 cites W2089346151 @default.
• W246691693 cites W2091916224 @default.
• W246691693 cites W2105998191 @default.
• W246691693 cites W2108495871 @default.
• W246691693 cites W2116899507 @default.
• W246691693 cites W2118370946 @default.
• W246691693 cites W2121897924 @default.
• W246691693 cites W2127450004 @default.
• W246691693 cites W2147070585 @default.
• W246691693 cites W2149568646 @default.
• W246691693 cites W2159722148 @default.
• W246691693 cites W2162073421 @default.
• W246691693 cites W2168733687 @default.
• W246691693 cites W2170951162 @default.
• W246691693 cites W2221055924 @default.
• W246691693 cites W2396160366 @default.
• W246691693 cites W4210968471 @default.
• W246691693 cites W4250468389 @default.
• W246691693 doi "https://doi.org/10.1016/j.freeradbiomed.2015.05.016" @default.
• W246691693 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26001728" @default.
• W246691693 hasPublicationYear "2015" @default.
• W246691693 type Work @default.
• W246691693 sameAs 246691693 @default.
• W246691693 citedByCount "30" @default.
• W246691693 countsByYear W2466916932015 @default.
• W246691693 countsByYear W2466916932016 @default.
• W246691693 countsByYear W2466916932017 @default.
• W246691693 countsByYear W2466916932018 @default.
• W246691693 countsByYear W2466916932019 @default.
• W246691693 countsByYear W2466916932020 @default.
• W246691693 countsByYear W2466916932021 @default.
• W246691693 countsByYear W2466916932022 @default.
• W246691693 countsByYear W2466916932023 @default.
• W246691693 crossrefType "journal-article" @default.
• W246691693 hasAuthorship W246691693A5011050819 @default.
• W246691693 hasAuthorship W246691693A5033952822 @default.
• W246691693 hasAuthorship W246691693A5044343654 @default.
• W246691693 hasAuthorship W246691693A5045131182 @default.
• W246691693 hasAuthorship W246691693A5060052335 @default.
• W246691693 hasAuthorship W246691693A5061755880 @default.
• W246691693 hasAuthorship W246691693A5078756031 @default.

• next